C4 Therapeutics received upgraded analyst ratings in early June 2026. Zacks issued a 'Buy' rating on June 1. These upgrades reflect an upward trend in earnings estimates. They also reflect growing confidence in cemsidomide, the company's lead drug candidate for relapsed/refractory multiple myeloma.
The favorable outlook stems from cemsidomide's steady clinical advancement. C4 initiated a Phase 2 trial in February 2026. It initiated a Phase 1b combination trial in March 2026. Positive results from competitors using similar drug mechanisms de-risk C4's therapeutic approach. These results bolster analyst and investor confidence in the drug's potential.